Daewoong terminates Nabota clinical trial plans in China, plans refiling
Oct 4, 2018
South Korea’s Daewoong Pharmaceutical said Thursday that it had voluntarily terminated its clinical trial application for its type A botulinum toxin drug Nabota that was approved by China’s drug regulator in January, citing the need for a production site change. The firm plans to submit a revised CTA by the year’s end, it added. After submitting the CTA and successfully obtaining approval, Daewoong expects that it can initiate phase 3 trials for Nabota, to prove the drug’s efficacy in treating f